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Like total ghrelin, acylated ghrelin
is also lower in HD patients with
cardiovascular disease
To the Editor: Recently, Carrero et al.1 showed that lower
total plasma ghrelin is associated with increased total and
cardiovascular mortality in protein–energy wasting hemo-
dialysis (HD) patients. However, total ghrelin includes both
acylated and des-acylated forms, with different biological
actions.2
We assessed acylated ghrelin (A-Ghr) in 20 healthy volun-
teers (57.00±8.62 years) and 68 HD patients (61.24±12.51
years, 22 diabetics). Samples were drawn before 2 years,
and at the end of this period 22 HD patients suffered
from coronary heart disease (CHD). Plasma A-Ghr was
measured using enzyme-linked immunosorbent assay (SPI
Bio, Montigny, France). White blood cell count (WBC),
C-reactive protein (CRP), and albumin were also assessed.
A-Ghr did not differ between HD patients and healthy
volunteers (106.40±27.53 versus 120.50±45.04pg/ml, P¼ 0.424,
Mann–Whitney unpaired test). A-Ghr was lower in HD patients
suffering from CHD (95.00±22.04 versus 111.85±28.42pg/ml,
P¼ 0.023) and was positively correlated with WBC (Spearman’s
r¼ 0.426, Po0.001), CRP (r¼ 0.261, P¼ 0.023), that is, with
inﬂammation, and age (r¼ 0.323, P¼ 0.007). A-Ghr was
negatively correlated with the marker of nutrition albumin
(r¼0.368, P¼ 0.002).
Thus, similar to total ghrelin, A-Ghr is also lower in HD
patients with cardiovascular disease. This could be simply an
epiphenomenon, as in the case of cachexia that accompanies
inﬂammation, A-Ghr increases to counteract weight-loss
mechanisms, and it is well known that inﬂammation also
induces atherosclerosis.2,3 Alternatively, higher A-Ghr could
offer protection from atherosclerosis through its direct action
on the endothelium or indirectly by attenuating inﬂamma-
tion.2,4 The second case, if proved true, is promising for
pharmaceutical intervention in the near future.
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The Authors Reply: We thank Eleftheriadis et al.1 for their
interest in our work.2 We believe that our observations
regarding the confounding effect of pre-existing protein–
energy wasting on the associations of ghrelin with inﬂamma-
tion, leptin, and outcome2 help to reconcile apparent
discrepancies between epidemiological3 and interventional
studies4 on the existence of a resistance to the action of
ghrelin in chronic kidney disease. Their report that there is no
difference in acylated ghrelin between healthy volunteers and
hemodialysis patients, but reduced acylated ghrelin in patients
with cardiovascular disease, may as well represent, as they
indicate, the epiphenomenon of concurrent cachexia. The
inability of observational studies to denote causality in these
associations warrants altogether the need to delve deeper into
the effects of ghrelin administration in the outcome of dialysis
patients. Ghrelin is truly an exciting therapeutic agent with a
range of purported beneﬁcial effects not only on anorexia but
also on inﬂammation and the cardiac system, and new
treatment strategies to tackle the excess mortality of this
patient group are urgently needed. However, we still have
some questions to address: although animal studies suggest
that acylated ghrelin stimulates appetite, Barazzoni et al.5
postulated that relative acylated ghrelin excess could con-
tribute to obesity-associated insulin resistance in metabolic
syndrome. The risks of developing ghrelin resistance, its
mitogenic potential, and the costs for ghrelin treatment also
need consideration.6 Although a small-scale clinical trial4 has
provided encouraging evidence on the short-term orexigenic
effects of subcutaneous acylated ghrelin administration
(1 week) in malnourished dialysis patients, we need still
to proceed cautiously until these concerns are clariﬁed.
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